Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
NCT ID: NCT06499857
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
200 participants
INTERVENTIONAL
2025-04-14
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two large longitudinal cohort studies demonstrated that obesity contributes to disease progression to persistent or permanent forms of AF. Importantly, significant weight loss achieved by bariatric surgery has been associated with a reduction in the risk of new-onset AF by 29% in the prospective matched cohort Swedish Obese Study. Weight loss achieved with intensive lifestyle modification has also been shown to impact AF burden. However, these studies have not systematically investigated the biological mechanisms underlying weight loss and AF.
The novelty of the proposed study is that it will be the first to examine the impact of weight loss with semaglutide 2.4 mg on biological signaling and cardiac remodeling in relation to reductions in AF burden. Additionally, the proposed study will be the first to evaluate the effect of pharmacological weight loss on the risk of arrhythmia recurrence, combined with antiarrhythmic drugs (AAD) and/or catheter ablation (CA), which are the current first-line strategies for rhythm maintenance in patients with obesity. That is relevant as obesity is a chronic and relapsing health condition as demonstrated in multiple large intensive lifestyle modification studies which show a significant weight loss in the short term but minimal weight reduction in the long-term follow up. Pharmacotherapy has been shown to be superior to lifestyle modification to achieve larger and maintained weight loss.
Therefore, The investigators propose the first-ever double-blinded placebo controlled randomized clinical study to assess the efficacy and impact of an anti-obesity medication on atrial fibrillation in patients receiving contemporary therapies for atrial fibrillation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Semaglutide
Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).
Semaglutide
3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
Placebo
Participants will have a 1 in 3 chance of receiving placebo.
Placebo
3ml pen-injector containing placebo solution for subcutaneous use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semaglutide
3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
Placebo
3ml pen-injector containing placebo solution for subcutaneous use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI greater than or equal to 30 kg/m2
3. Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
4. Ability to provide informed consent before any trial-related activities.
5. Patients with type 2 diabetes mellitus (T2DM) will be included:
1. If HbA1c (glycated hemoglobin) is less than or equal to 10 %
2. If the subject is taking basal insulin only or oral hypoglycemic agents or a combination of those.
3. Patients on SGLT2-inhibitors and TZDs (Thiazolidinedione) will be included if they have been on a stable dose of these medications for at least 6 months
4. The following protocol will be adopted to adjust insulin secretagogues (sulfonylureas or meglitinides) and insulin during the study (adapted from the Look Ahead Study).
Patients will be asked to check their blood glucose (BG) 4 x day (before meals and at bed time) during the dose escalation and dose stabilization phases (weeks 0 to 20) and recommendation of dose adjustments will be immediately sent to their treating physician according to the dose adjustment scale below:
* 2 blood sugars \<100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 0-50 %
* 3 blood sugars 80-100 mg/dl- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 25-75%
* 3 blood sugars \<80 mg/dl \> 2 x week or severe hypoglycemia or symptomatic hypoglycemia- reduce meds \[insulin secretagogues (sulfonylureas or meglitinides) and basal insulin\] by 50-100 %
Randomization to treatment (active and placebo) will be stratified to balance patients with T2DM across the study arms. After completion of the trial a prespecified subgroup analysis of the patients enrolled affected by T2DM will be performed.
For women of child-bearing potential, use of appropriate contraception will be required.
In patients that are prescribed amiodarone, standard care practices will be implemented to evaluate for liver and thyroid side effects with baseline liver and thyroid function tests via blood draw and evaluation every 6 months.
Exclusion Criteria
2. Current antiobesity medication use or use within the last 90 days prior to screening
3. A self-reported change in body weight of \> 5 kg (11 lb.) within 30 days before screening
4. History of bariatric surgery
5. History of type I diabetes mellitus
6. Current use of prandial insulin
7. Hospitalization for unstable angina, or TIA (Transient ischemic attack) \< 30 days prior to screening
8. Pulmonary embolism \< 90 days before screening
9. MI (myocardial infarction), stroke, etc. \< 90 months prior to screening
10. Uncontrolled thyroid disease: TSH (Thyroid-stimulating hormone) \> 10.0 mIU/L (Milli-international Units Per Liter) or \< 0.4 mIU/L (Milli-international Units Per Liter) at screening
11. Active malignancy
12. Active enrollment in another investigational study that includes any kind of intervention
13. The receipt of any investigational drug within 90 days prior to this trial.
14. Inability to comply with study procedures
15. Acute pancreatitis \< 180 days before screening
16. History or presence of chronic pancreatitis
17. CKD (Chronic Kidney Disease) stage 4 (GFR \<30 ml/min)
18. A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
19. A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY
20. Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids
21. Previous participation in this trial (received at least one dose of study drug or placebo)
22. Pregnant, breast-feeding or planning pregnancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvana Pannain, MD
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Arizona College of Medicine- Phoenix
Phoenix, Arizona, United States
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Roderick Tung, MD
Role: primary
Silvana Pannain, MD
Role: primary
Andrew Beaser, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB23-0889
Identifier Type: -
Identifier Source: org_study_id